rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BMEA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
      Nov 10Yahoo FinanceBMEA
      Biomea Fusion to present Phase 1 data for oral GLP-1 drug
      Nov 10Investing.comBMEA
      Citizens reiterates Biomea Fusion stock rating on Phase 1 data
      Oct 14Investing.comBMEA
      What’s Going On With Biomea Fusion (BMEA) Stock After Hours? - Biomea Fusion (NASDAQ:BMEA)

      Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.

      Oct 14BenzingaBMEA
      Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow (NASDAQ:BMEA) 2026-10-14

      2026-10-14. The following slide deck was published by Biomea Fusion, Inc.

      Oct 14Seeking AlphaBMEA
      Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
      Oct 14Yahoo FinanceBMEA
      Biomea Fusion reports weight loss data from oral GLP-1 trial
      Oct 13Investing.comBMEA
      Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
      Oct 13Yahoo FinanceBMEA
      Biomea Fusion Stock Climbs 7% After-Hours: What's Going On? - Biomea Fusion (NASDAQ:BMEA)

      Biomea Fusion shares rise after-hours before Phase I results for oral GLP-1 candidate BMF-650.

      Oct 13BenzingaBMEA
      Biomea Fusion to report Phase I trial results Tuesday
      Oct 12Investing.comBMEA
      12 Health Care Stocks Moving In Monday's After-Market Session - Biomea Fusion (NASDAQ:BMEA), iTonic Holdi

      Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings (NASDAQ:ITOC) shares

      Oct 12BenzingaBMEADARE
      Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
      Oct 12Yahoo FinanceBMEA
      Brookline Capital initiates Biomea Fusion stock with buy rating
      Oct 7Investing.comBMEA
      Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation
      Sep 30Investing.comBMEA
      Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA)
      Sep 24Seeking AlphaBMEA
      Biomea Fusion Shares Fall After Terminating Proposed Public Offering

      Biomea Fusion (BMEA) shares were down over 19% in Wednesday trading after the company said it termin

      Sep 23Yahoo FinanceBMEA
      Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - Biomea Fusion (NASDAQ:BMEA)

      Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.

      Sep 23BenzingaBMEA
      Biomea slips after halting stock offering, delaying trial readout
      Sep 23Seeking AlphaBMEA
      Biomea Fusion stock ticks up after canceling public offering
      Sep 23Investing.comBMEA
      Biomea Fusion terminates proposed public offering
      Sep 23Investing.comBMEA
      Biomea Fusion Announces Termination of Proposed Public Offering of Securities
      Sep 23Yahoo FinanceBMEA
      Biomea Fusion Shares Fall 19% After Hours: Here’s Why - Biomea Fusion (NASDAQ:BMEA)

      Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.

      Sep 23BenzingaBMEA
      Biomea Fusion stock tumbles on public offering launch
      Sep 22Investing.comBMEA
      Biomea Fusion announces public offering of common stock
      Sep 22Investing.comBMEA
      Biomea Fusion Proposes Public Offering of Common Stock, Pre-Funded Warrants

      Biomea Fusion (BMEA) said late Tuesday it has commenced an underwritten public offering of its commo

      Sep 22Yahoo FinanceBMEA
      Biomea Fusion Announces Proposed Public Offering of Securities

      SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total numb

      Sep 22Yahoo FinanceBMEA
      Biomea Fusion, Inc. (BMEA) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow (NASDAQ:BMEA) 2026-09-16
      Sep 16Seeking AlphaBMEA
      After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

      Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

      Sep 4Yahoo FinanceBMEA
      Biomea Fusion to Participate in Upcoming Investor Conferences

      SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.H.C. Wainwright 28th Annual Global Investment Confere

      Sep 3Yahoo FinanceBMEA
      Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
      Aug 24BenzingaBMEA
      Biomea Fusion stock surges on diabetes trial enrollment completion
      Aug 24Investing.comBMEA
      H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment
      Aug 24Investing.comBMEA
      Why is Biomea Fusion stock climbing today?
      Aug 24Investing.comBMEA
      Biomea Fusion completes enrollment in diabetes trial
      Aug 24Investing.comBMEA
      Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

      Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027These ongoing Phase II diabetes trials target two distinct

      Aug 24Yahoo FinanceBMEA
      Biomea Shares Rise After Completing Enrollment in Diabetes Trial

      Biomea Fusion (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enr

      Aug 24Yahoo FinanceBMEA
      Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
      Aug 22Yahoo FinanceBMEA

      This is the newest page. Registered accounts read further back.